Abbott Laboratories (ABT)

[DewDiligence]

ABT 2021 non-GAAP EPS=$5.21, above the prior guidance range of $5.00-5.10 due to a surge in COVID diagnostics sales in December related to Omicron.

ABT’s 2022 non-GAAP-EPS guidance is >=$4.70 (-10% YoY) due to lower expected sales of COVID diagnostics, which were $7.7B(!) in 2021 and $2.3B in 4Q21.

4Q21 PR:
https://abbott.mediaroom.com/2022-01-26-Abbott-Reports-Strong-Fourth-Quarter-2021-Results-Issues-2022-Forecast

1-page summary sheet:
https://www.abbottinvestor.com/static-files/d7299f5f-28d7-4f48-aaf8-729bfc7c4157